LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

LLY

748.42

+1.7%↑

JNJ

177.03

-0.47%↓

ABBV

209.99

+0.36%↑

UNH

348.72

+8.76%↑

NVO

53.9

-0.77%↓

Search

Alcon Inc

Open

BrancheGesundheitswesen

78.89 -1.34

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

78.69

Max

79.95

Schlüsselkennzahlen

By Trading Economics

Einkommen

-167M

183M

Verkäufe

123M

2.6B

KGV

Branchendurchschnitt

36.949

35.733

Dividendenrendite

0.42

Gewinnspanne

7.058

Angestellte

25,000

EBITDA

-213M

250M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+23.1% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.42%

3.13%

Nächstes Ergebnis

11. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-4.3B

40B

Vorheriger Eröffnungskurs

80.23

Vorheriger Schlusskurs

78.89

Nachrichtenstimmung

By Acuity

10%

90%

13 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Alcon Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Sept. 2025, 23:07 UTC

Akquisitionen, Fusionen, Übernahmen

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

20. Aug. 2025, 17:21 UTC

Ergebnisse
Wichtige Markttreiber

Alcon Shares Sink After Cut to Fiscal Year Sales Guidance

20. Aug. 2025, 08:46 UTC

Ergebnisse
Wichtige Markttreiber

Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit

5. Aug. 2025, 10:10 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon to Buy Staar Surgical for $1.5 Billion

14. Mai 2025, 15:56 UTC

Ergebnisse
Wichtige Markttreiber

Alcon Shares Fall After Lowering 2025 Outlook

26. März 2025, 21:22 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

20. Aug. 2025, 17:06 UTC

Ergebnisse
Wichtige Markttreiber

Alcon Shares Sink After Cut to FY Sales Guidance

19. Aug. 2025, 20:32 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Alcon Cuts 2025 View To Sales $10.3B-$10.4B >ALC.EB

19. Aug. 2025, 20:31 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Alcon 2Q EPS 35c >ALC.EB

19. Aug. 2025, 20:30 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Alcon 2Q Sales $2.58B >ALC.EB

19. Aug. 2025, 20:30 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr And Announced Acquisition Of STAAR Surgical >ALC

8. Aug. 2025, 13:40 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Staar Surgical's Top Holder Questions Deal -- Market Talk

5. Aug. 2025, 05:07 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Deal Puts STARR Equity Value at Approximately $1.5 Billion. >ALC.EB

5. Aug. 2025, 05:07 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Will Purchase All Outstanding Shares of STAAR Common Stock for $28 Per Share in Cash >ALC.EB

5. Aug. 2025, 05:07 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Deal Represents 51% Premium to Closing Price of STAAR Common Stock on Aug. 4 >ALC.EB

5. Aug. 2025, 05:07 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Agrees to Acquire STAAR Surgical >ALC STAA

5. Aug. 2025, 05:01 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Agrees To Acquire STAAR Surgical >ALC STAA

7. Juli 2025, 12:00 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon To Acquire LumiThera And Its Photobiomodulation Device For The Treatment Of Early And Intermediate Dry Age-Related Macular Degeneration (AMD) >ALC

30. Mai 2025, 06:32 UTC

Market Talk
Ergebnisse

Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

22. Mai 2025, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

13. Mai 2025, 20:32 UTC

Ergebnisse

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. Mai 2025, 20:31 UTC

Ergebnisse

Alcon 1Q Sales $2.45B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q Rev $2.47B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q EPS 70c >ALC.EB

8. Apr. 2025, 08:20 UTC

Market Talk

Med-Tech Investors Seek 'Safe Havens' Amid Tariff Fears -- Market Talk

26. März 2025, 21:55 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26. März 2025, 20:33 UTC

Akquisitionen, Fusionen, Übernahmen

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26. März 2025, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26. März 2025, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26. März 2025, 20:31 UTC

Akquisitionen, Fusionen, Übernahmen

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

Peer-Vergleich

Kursveränderung

Alcon Inc Prognose

Kursziel

By TipRanks

23.1% Vorteil

12-Monats-Prognose

Durchschnitt 98.69 USD  23.1%

Hoch 119.067 USD

Tief 77.53 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alcon Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

13

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

95.77 / 97.61Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

13 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
help-icon Live chat